Clinical Trials Directory

Trials / Completed

CompletedNCT00673621

A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics

A Phase 1, Open-Label, Controlled Clinical Trial to Evaluate Pharmacokinetics After Administration of Technosphere® Insulin Inhalation Powder Alone and With Salbutamol (Albuterol) and/or After Methacholine Challenge Testing in Subjects With Asthma Versus Matched Healthy Subjects Without Asthma

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Mannkind Corporation · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This study will compare the rate and extent of absorption of TI Inhalation Powder in subjects with asthma and subjects with normal lung function. 24 eligible subjects will be enrolled into the treatment phase of the trial.

Detailed description

Visit 1 screening will determine eligibility and obtain informed consent. At visit 2, 3 and 4 subjects inhale 1 dose of 45U TI Inhalation Powder. At visit 3 subjects inhale 2 puffs (200mcg) Albuterol prior to dosing. Only asthmatic subjects undergo visit 4 where a methacholine challenge test (MCT) is performed followed by inhalation of Albuterol then administration of TI Inhalation Powder. Each visit's dosing will occur during a hyperinsulinemic euglycemic clamp. Visit 5 is the follow up visit.

Conditions

Interventions

TypeNameDescription
DRUGTechnosphere Insulin Inhalation Powder3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
DRUGSalbutamol (Albuterol)2 puff = 200 mcg total dose
DRUGMethacholine chloride5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%

Timeline

Start date
2008-05-01
Primary completion
2008-11-01
Completion
2008-12-01
First posted
2008-05-07
Last updated
2012-06-13

Locations

2 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00673621. Inclusion in this directory is not an endorsement.